nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—ABCG2—Dactinomycin—ocular cancer	0.0691	0.36	CbGbCtD
Sunitinib—ABCC2—Carboplatin—ocular cancer	0.0514	0.268	CbGbCtD
Sunitinib—ABCG2—Carboplatin—ocular cancer	0.0464	0.242	CbGbCtD
Sunitinib—ABCB1—Dactinomycin—ocular cancer	0.0249	0.13	CbGbCtD
Sunitinib—SBK1—cornea—ocular cancer	0.0207	0.0868	CbGeAlD
Sunitinib—FGFR2—cornea—ocular cancer	0.00972	0.0408	CbGeAlD
Sunitinib—FGFR2—skull—ocular cancer	0.00544	0.0228	CbGeAlD
Sunitinib—GRK7—eye—ocular cancer	0.00455	0.0191	CbGeAlD
Sunitinib—GRK7—retina—ocular cancer	0.00451	0.0189	CbGeAlD
Sunitinib—GRK1—eye—ocular cancer	0.00329	0.0138	CbGeAlD
Sunitinib—NIM1K—retina—ocular cancer	0.00326	0.0137	CbGeAlD
Sunitinib—GRK1—retina—ocular cancer	0.00326	0.0137	CbGeAlD
Sunitinib—PIP4K2B—eye—ocular cancer	0.00315	0.0132	CbGeAlD
Sunitinib—ERN1—epithelium—ocular cancer	0.00288	0.0121	CbGeAlD
Sunitinib—MYLK4—lymphoid tissue—ocular cancer	0.00272	0.0114	CbGeAlD
Sunitinib—SBK1—eye—ocular cancer	0.00255	0.0107	CbGeAlD
Sunitinib—SBK1—retina—ocular cancer	0.00253	0.0106	CbGeAlD
Sunitinib—RPS6KA1—eye—ocular cancer	0.00239	0.01	CbGeAlD
Sunitinib—ERN1—lymphoid tissue—ocular cancer	0.00222	0.00932	CbGeAlD
Sunitinib—STK11—epithelium—ocular cancer	0.00221	0.00927	CbGeAlD
Sunitinib—NUAK1—retina—ocular cancer	0.0022	0.00924	CbGeAlD
Sunitinib—RPS6KA2—retina—ocular cancer	0.00215	0.00902	CbGeAlD
Sunitinib—STK17B—lymphoid tissue—ocular cancer	0.00214	0.00897	CbGeAlD
Sunitinib—PKN1—eye—ocular cancer	0.00213	0.00896	CbGeAlD
Sunitinib—CSNK1G2—retina—ocular cancer	0.00212	0.00888	CbGeAlD
Sunitinib—PKN1—retina—ocular cancer	0.00212	0.00888	CbGeAlD
Sunitinib—PRPF4—eye—ocular cancer	0.0021	0.00883	CbGeAlD
Sunitinib—PRPF4—retina—ocular cancer	0.00208	0.00875	CbGeAlD
Sunitinib—STK39—eye—ocular cancer	0.00204	0.00858	CbGeAlD
Sunitinib—STK39—retina—ocular cancer	0.00203	0.00851	CbGeAlD
Sunitinib—CSNK2A1—retina—ocular cancer	0.002	0.00839	CbGeAlD
Sunitinib—MYLK—eye—ocular cancer	0.00199	0.00836	CbGeAlD
Sunitinib—MYLK—retina—ocular cancer	0.00197	0.00829	CbGeAlD
Sunitinib—STK17A—lymphoid tissue—ocular cancer	0.00197	0.00827	CbGeAlD
Sunitinib—STK24—eye—ocular cancer	0.00191	0.00802	CbGeAlD
Sunitinib—STK24—retina—ocular cancer	0.00189	0.00794	CbGeAlD
Sunitinib—HIPK3—retina—ocular cancer	0.00183	0.00769	CbGeAlD
Sunitinib—MYLK—epithelium—ocular cancer	0.00182	0.00765	CbGeAlD
Sunitinib—CLK4—lymphoid tissue—ocular cancer	0.00182	0.00763	CbGeAlD
Sunitinib—ITK—lymphoid tissue—ocular cancer	0.0018	0.00754	CbGeAlD
Sunitinib—MAP4K1—retina—ocular cancer	0.00179	0.00753	CbGeAlD
Sunitinib—BLK—lymphoid tissue—ocular cancer	0.00178	0.00745	CbGeAlD
Sunitinib—DAPK1—lymphoid tissue—ocular cancer	0.00176	0.00737	CbGeAlD
Sunitinib—STK3—eye—ocular cancer	0.00173	0.00725	CbGeAlD
Sunitinib—ROCK1—eye—ocular cancer	0.0017	0.00716	CbGeAlD
Sunitinib—BRD4—lymphoid tissue—ocular cancer	0.0017	0.00714	CbGeAlD
Sunitinib—STK11—lymphoid tissue—ocular cancer	0.0017	0.00714	CbGeAlD
Sunitinib—ROCK1—retina—ocular cancer	0.00169	0.00709	CbGeAlD
Sunitinib—MERTK—eye—ocular cancer	0.00162	0.00682	CbGeAlD
Sunitinib—MERTK—retina—ocular cancer	0.00161	0.00675	CbGeAlD
Sunitinib—MAP3K12—eye—ocular cancer	0.00157	0.0066	CbGeAlD
Sunitinib—ROCK1—epithelium—ocular cancer	0.00156	0.00654	CbGeAlD
Sunitinib—SNRK—lymphoid tissue—ocular cancer	0.00155	0.00651	CbGeAlD
Sunitinib—INSR—lymphoid tissue—ocular cancer	0.00155	0.00651	CbGeAlD
Sunitinib—MAP2K1—eye—ocular cancer	0.00154	0.00646	CbGeAlD
Sunitinib—RPS6KA3—retina—ocular cancer	0.00154	0.00645	CbGeAlD
Sunitinib—RPS6KA2—lymphoid tissue—ocular cancer	0.00153	0.00641	CbGeAlD
Sunitinib—STK38—lymphoid tissue—ocular cancer	0.00153	0.00641	CbGeAlD
Sunitinib—CSNK1A1—eye—ocular cancer	0.00152	0.00638	CbGeAlD
Sunitinib—CLK1—eye—ocular cancer	0.00151	0.00634	CbGeAlD
Sunitinib—PKN1—lymphoid tissue—ocular cancer	0.0015	0.00631	CbGeAlD
Sunitinib—CSNK1G2—lymphoid tissue—ocular cancer	0.0015	0.00631	CbGeAlD
Sunitinib—CLK1—retina—ocular cancer	0.0015	0.00628	CbGeAlD
Sunitinib—CAMK2G—eye—ocular cancer	0.00148	0.00622	CbGeAlD
Sunitinib—PRPF4—lymphoid tissue—ocular cancer	0.00148	0.00622	CbGeAlD
Sunitinib—PRPF4B—lymphoid tissue—ocular cancer	0.00146	0.00613	CbGeAlD
Sunitinib—FLT4—eye—ocular cancer	0.00143	0.00599	CbGeAlD
Sunitinib—MAP2K1—epithelium—ocular cancer	0.00141	0.00591	CbGeAlD
Sunitinib—MYLK—lymphoid tissue—ocular cancer	0.0014	0.00589	CbGeAlD
Sunitinib—CSNK1E—retina—ocular cancer	0.0014	0.00586	CbGeAlD
Sunitinib—PLK4—lymphoid tissue—ocular cancer	0.00139	0.00582	CbGeAlD
Sunitinib—STK4—lymphoid tissue—ocular cancer	0.00138	0.00578	CbGeAlD
Sunitinib—ULK3—eye—ocular cancer	0.00136	0.00569	CbGeAlD
Sunitinib—ULK3—retina—ocular cancer	0.00134	0.00564	CbGeAlD
Sunitinib—MAP3K7—retina—ocular cancer	0.00132	0.00554	CbGeAlD
Sunitinib—TBK1—eye—ocular cancer	0.00132	0.00553	CbGeAlD
Sunitinib—TYK2—eye—ocular cancer	0.00131	0.00549	CbGeAlD
Sunitinib—STK16—lymphoid tissue—ocular cancer	0.00131	0.00549	CbGeAlD
Sunitinib—FLT4—epithelium—ocular cancer	0.00131	0.00548	CbGeAlD
Sunitinib—HIPK2—lymphoid tissue—ocular cancer	0.0013	0.00546	CbGeAlD
Sunitinib—TYRO3—lymphoid tissue—ocular cancer	0.0013	0.00546	CbGeAlD
Sunitinib—ALK—lymphoid tissue—ocular cancer	0.0013	0.00546	CbGeAlD
Sunitinib—TYK2—retina—ocular cancer	0.0013	0.00544	CbGeAlD
Sunitinib—MAP4K1—lymphoid tissue—ocular cancer	0.00128	0.00535	CbGeAlD
Sunitinib—RPS6KB1—eye—ocular cancer	0.00127	0.00532	CbGeAlD
Sunitinib—RPS6KB1—retina—ocular cancer	0.00126	0.00527	CbGeAlD
Sunitinib—AXL—eye—ocular cancer	0.00125	0.00527	CbGeAlD
Sunitinib—AXL—retina—ocular cancer	0.00124	0.00522	CbGeAlD
Sunitinib—CLK2—lymphoid tissue—ocular cancer	0.00124	0.0052	CbGeAlD
Sunitinib—MAP4K2—lymphoid tissue—ocular cancer	0.00123	0.00518	CbGeAlD
Sunitinib—ROCK1—lymphoid tissue—ocular cancer	0.0012	0.00504	CbGeAlD
Sunitinib—FGFR2—eye—ocular cancer	0.0012	0.00503	CbGeAlD
Sunitinib—DYRK1A—lymphoid tissue—ocular cancer	0.00117	0.00492	CbGeAlD
Sunitinib—RPS6KB1—epithelium—ocular cancer	0.00116	0.00487	CbGeAlD
Sunitinib—RET—epithelium—ocular cancer	0.00115	0.00484	CbGeAlD
Sunitinib—MERTK—lymphoid tissue—ocular cancer	0.00114	0.0048	CbGeAlD
Sunitinib—MAP4K4—lymphoid tissue—ocular cancer	0.00112	0.00471	CbGeAlD
Sunitinib—FLT1—eye—ocular cancer	0.00111	0.00466	CbGeAlD
Sunitinib—FLT3—lymphoid tissue—ocular cancer	0.00111	0.00465	CbGeAlD
Sunitinib—FLT1—retina—ocular cancer	0.0011	0.00462	CbGeAlD
Sunitinib—FGFR2—epithelium—ocular cancer	0.0011	0.0046	CbGeAlD
Sunitinib—RPS6KA3—lymphoid tissue—ocular cancer	0.00109	0.00458	CbGeAlD
Sunitinib—JAK2—epithelium—ocular cancer	0.00109	0.00457	CbGeAlD
Sunitinib—MAP2K1—lymphoid tissue—ocular cancer	0.00108	0.00455	CbGeAlD
Sunitinib—CSNK1A1—lymphoid tissue—ocular cancer	0.00107	0.00449	CbGeAlD
Sunitinib—CLK1—lymphoid tissue—ocular cancer	0.00106	0.00446	CbGeAlD
Sunitinib—YES1—eye—ocular cancer	0.00106	0.00445	CbGeAlD
Sunitinib—YES1—retina—ocular cancer	0.00105	0.00441	CbGeAlD
Sunitinib—TAOK3—eye—ocular cancer	0.00105	0.00439	CbGeAlD
Sunitinib—TAOK3—retina—ocular cancer	0.00104	0.00435	CbGeAlD
Sunitinib—PRKAA1—lymphoid tissue—ocular cancer	0.00102	0.00428	CbGeAlD
Sunitinib—FLT1—epithelium—ocular cancer	0.00102	0.00426	CbGeAlD
Sunitinib—PTK2B—lymphoid tissue—ocular cancer	0.00101	0.00423	CbGeAlD
Sunitinib—FLT4—lymphoid tissue—ocular cancer	0.00101	0.00422	CbGeAlD
Sunitinib—IRAK4—lymphoid tissue—ocular cancer	0.000976	0.0041	CbGeAlD
Sunitinib—MAP2K2—lymphoid tissue—ocular cancer	0.000955	0.00401	CbGeAlD
Sunitinib—MAP3K2—lymphoid tissue—ocular cancer	0.000948	0.00398	CbGeAlD
Sunitinib—KDR—eye—ocular cancer	0.000938	0.00394	CbGeAlD
Sunitinib—KDR—retina—ocular cancer	0.00093	0.0039	CbGeAlD
Sunitinib—TBK1—lymphoid tissue—ocular cancer	0.000928	0.0039	CbGeAlD
Sunitinib—TYK2—lymphoid tissue—ocular cancer	0.000922	0.00387	CbGeAlD
Sunitinib—CSF1R—eye—ocular cancer	0.000915	0.00384	CbGeAlD
Sunitinib—RPS6KB1—lymphoid tissue—ocular cancer	0.000893	0.00375	CbGeAlD
Sunitinib—RET—lymphoid tissue—ocular cancer	0.000888	0.00373	CbGeAlD
Sunitinib—FGR—lymphoid tissue—ocular cancer	0.000888	0.00373	CbGeAlD
Sunitinib—AXL—lymphoid tissue—ocular cancer	0.000884	0.00371	CbGeAlD
Sunitinib—KDR—epithelium—ocular cancer	0.000858	0.0036	CbGeAlD
Sunitinib—JAK2—lymphoid tissue—ocular cancer	0.000839	0.00352	CbGeAlD
Sunitinib—FYN—lymphoid tissue—ocular cancer	0.000827	0.00347	CbGeAlD
Sunitinib—PDGFRB—eye—ocular cancer	0.000812	0.00341	CbGeAlD
Sunitinib—MAP4K5—lymphoid tissue—ocular cancer	0.000809	0.00339	CbGeAlD
Sunitinib—FLT1—lymphoid tissue—ocular cancer	0.000782	0.00328	CbGeAlD
Sunitinib—KIT—epithelium—ocular cancer	0.00076	0.00319	CbGeAlD
Sunitinib—YES1—lymphoid tissue—ocular cancer	0.000747	0.00313	CbGeAlD
Sunitinib—PDGFRB—epithelium—ocular cancer	0.000743	0.00312	CbGeAlD
Sunitinib—STK10—lymphoid tissue—ocular cancer	0.00074	0.00311	CbGeAlD
Sunitinib—TAOK3—lymphoid tissue—ocular cancer	0.000737	0.00309	CbGeAlD
Sunitinib—PDGFRA—lymphoid tissue—ocular cancer	0.000733	0.00307	CbGeAlD
Sunitinib—KDR—lymphoid tissue—ocular cancer	0.000661	0.00277	CbGeAlD
Sunitinib—CSF1R—lymphoid tissue—ocular cancer	0.000645	0.00271	CbGeAlD
Sunitinib—KIT—lymphoid tissue—ocular cancer	0.000586	0.00246	CbGeAlD
Sunitinib—PDGFRB—lymphoid tissue—ocular cancer	0.000572	0.0024	CbGeAlD
Sunitinib—ABCB1—retina—ocular cancer	0.000223	0.000936	CbGeAlD
Sunitinib—ABCB1—epithelium—ocular cancer	0.000206	0.000864	CbGeAlD
Sunitinib—ABCB1—lymphoid tissue—ocular cancer	0.000159	0.000665	CbGeAlD
Sunitinib—Multi-organ failure—Dactinomycin—ocular cancer	0.000108	0.0899	CcSEcCtD
Sunitinib—Cheilitis—Dactinomycin—ocular cancer	8.31e-05	0.0689	CcSEcCtD
Sunitinib—Raised liver function tests—Dactinomycin—ocular cancer	7.65e-05	0.0635	CcSEcCtD
Sunitinib—Myelosuppression—Dactinomycin—ocular cancer	7.54e-05	0.0625	CcSEcCtD
Sunitinib—Febrile neutropenia—Dactinomycin—ocular cancer	5.87e-05	0.0487	CcSEcCtD
Sunitinib—Hepatotoxicity—Dactinomycin—ocular cancer	4.58e-05	0.038	CcSEcCtD
Sunitinib—Hypocalcaemia—Dactinomycin—ocular cancer	3.86e-05	0.032	CcSEcCtD
Sunitinib—Infection—Carboplatin—ocular cancer	3.37e-05	0.028	CcSEcCtD
Sunitinib—Oesophagitis—Dactinomycin—ocular cancer	3.23e-05	0.0268	CcSEcCtD
Sunitinib—Mouth ulceration—Dactinomycin—ocular cancer	3.2e-05	0.0265	CcSEcCtD
Sunitinib—Sepsis—Dactinomycin—ocular cancer	3.07e-05	0.0254	CcSEcCtD
Sunitinib—Pain—Carboplatin—ocular cancer	2.9e-05	0.0241	CcSEcCtD
Sunitinib—Hepatic failure—Dactinomycin—ocular cancer	2.85e-05	0.0237	CcSEcCtD
Sunitinib—Body temperature increased—Carboplatin—ocular cancer	2.68e-05	0.0223	CcSEcCtD
Sunitinib—Liver function test abnormal—Dactinomycin—ocular cancer	2.37e-05	0.0196	CcSEcCtD
Sunitinib—Toxic epidermal necrolysis—Dactinomycin—ocular cancer	2.31e-05	0.0192	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Dactinomycin—ocular cancer	2.31e-05	0.0192	CcSEcCtD
Sunitinib—Dysphagia—Dactinomycin—ocular cancer	2.22e-05	0.0184	CcSEcCtD
Sunitinib—Pancytopenia—Dactinomycin—ocular cancer	2.11e-05	0.0175	CcSEcCtD
Sunitinib—Neutropenia—Dactinomycin—ocular cancer	2.07e-05	0.0172	CcSEcCtD
Sunitinib—Pneumonia—Dactinomycin—ocular cancer	1.99e-05	0.0165	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Dactinomycin—ocular cancer	1.96e-05	0.0163	CcSEcCtD
Sunitinib—Stomatitis—Dactinomycin—ocular cancer	1.93e-05	0.016	CcSEcCtD
Sunitinib—Hepatitis—Dactinomycin—ocular cancer	1.77e-05	0.0147	CcSEcCtD
Sunitinib—Erythema multiforme—Dactinomycin—ocular cancer	1.68e-05	0.0139	CcSEcCtD
Sunitinib—Flushing—Dactinomycin—ocular cancer	1.65e-05	0.0137	CcSEcCtD
Sunitinib—Chills—Dactinomycin—ocular cancer	1.59e-05	0.0132	CcSEcCtD
Sunitinib—Alopecia—Dactinomycin—ocular cancer	1.57e-05	0.013	CcSEcCtD
Sunitinib—Erythema—Dactinomycin—ocular cancer	1.54e-05	0.0128	CcSEcCtD
Sunitinib—Anaemia—Dactinomycin—ocular cancer	1.43e-05	0.0118	CcSEcCtD
Sunitinib—Leukopenia—Dactinomycin—ocular cancer	1.38e-05	0.0115	CcSEcCtD
Sunitinib—Myalgia—Dactinomycin—ocular cancer	1.32e-05	0.0109	CcSEcCtD
Sunitinib—Oedema—Dactinomycin—ocular cancer	1.26e-05	0.0105	CcSEcCtD
Sunitinib—Infection—Dactinomycin—ocular cancer	1.25e-05	0.0104	CcSEcCtD
Sunitinib—Thrombocytopenia—Dactinomycin—ocular cancer	1.23e-05	0.0102	CcSEcCtD
Sunitinib—Anorexia—Dactinomycin—ocular cancer	1.2e-05	0.00997	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Dactinomycin—ocular cancer	1.15e-05	0.00953	CcSEcCtD
Sunitinib—Decreased appetite—Dactinomycin—ocular cancer	1.1e-05	0.00909	CcSEcCtD
Sunitinib—Fatigue—Dactinomycin—ocular cancer	1.09e-05	0.00901	CcSEcCtD
Sunitinib—Pain—Dactinomycin—ocular cancer	1.08e-05	0.00894	CcSEcCtD
Sunitinib—Gastrointestinal pain—Dactinomycin—ocular cancer	1.03e-05	0.00855	CcSEcCtD
Sunitinib—Abdominal pain—Dactinomycin—ocular cancer	9.97e-06	0.00827	CcSEcCtD
Sunitinib—Body temperature increased—Dactinomycin—ocular cancer	9.97e-06	0.00827	CcSEcCtD
Sunitinib—Hypersensitivity—Dactinomycin—ocular cancer	9.29e-06	0.0077	CcSEcCtD
Sunitinib—Asthenia—Dactinomycin—ocular cancer	9.05e-06	0.0075	CcSEcCtD
Sunitinib—Diarrhoea—Dactinomycin—ocular cancer	8.63e-06	0.00715	CcSEcCtD
Sunitinib—Vomiting—Dactinomycin—ocular cancer	8.02e-06	0.00665	CcSEcCtD
Sunitinib—Rash—Dactinomycin—ocular cancer	7.95e-06	0.00659	CcSEcCtD
Sunitinib—Nausea—Dactinomycin—ocular cancer	7.49e-06	0.00621	CcSEcCtD
Sunitinib—PDGFRB—Disease—EP300—ocular cancer	5.26e-06	9.24e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—CCND1—ocular cancer	5.25e-06	9.23e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—CDKN1B—ocular cancer	5.22e-06	9.18e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—EP300—ocular cancer	5.22e-06	9.17e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—TP53—ocular cancer	5.17e-06	9.09e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—MYC—ocular cancer	5.17e-06	9.08e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—HRAS—ocular cancer	5.16e-06	9.07e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—TGFB1—ocular cancer	5.15e-06	9.06e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—GNAQ—ocular cancer	5.15e-06	9.05e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—MYC—ocular cancer	5.13e-06	9.03e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—TGFB1—ocular cancer	5.12e-06	9e-06	CbGpPWpGaD
Sunitinib—YES1—Immune System—HRAS—ocular cancer	5.12e-06	9e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MDM2—ocular cancer	5.11e-06	8.98e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—MYC—ocular cancer	5.1e-06	8.96e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MDM2—ocular cancer	5.1e-06	8.96e-06	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—AKT1—ocular cancer	5.1e-06	8.96e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—TGFB1—ocular cancer	5.09e-06	8.94e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—MYC—ocular cancer	5.08e-06	8.94e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—CDKN1A—ocular cancer	5.08e-06	8.93e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—TGFB1—ocular cancer	5.07e-06	8.92e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CDKN1B—ocular cancer	5.07e-06	8.91e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—EP300—ocular cancer	5.07e-06	8.91e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—CDKN1A—ocular cancer	5.06e-06	8.9e-06	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—AKT1—ocular cancer	5.06e-06	8.89e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—EP300—ocular cancer	5.04e-06	8.86e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CDKN1B—ocular cancer	5.01e-06	8.8e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—CCND1—ocular cancer	4.98e-06	8.76e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—MYC—ocular cancer	4.98e-06	8.75e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—MYC—ocular cancer	4.98e-06	8.75e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TGFB1—ocular cancer	4.97e-06	8.73e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TGFB1—ocular cancer	4.97e-06	8.73e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—HRAS—ocular cancer	4.95e-06	8.7e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CDKN1B—ocular cancer	4.92e-06	8.64e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CDKN1B—ocular cancer	4.92e-06	8.64e-06	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—HRAS—ocular cancer	4.85e-06	8.53e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—TP53—ocular cancer	4.85e-06	8.53e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—MYC—ocular cancer	4.85e-06	8.53e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TGFB1—ocular cancer	4.84e-06	8.51e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CCND1—ocular cancer	4.84e-06	8.5e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—EP300—ocular cancer	4.83e-06	8.5e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—CDKN1A—ocular cancer	4.82e-06	8.47e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—EP300—ocular cancer	4.82e-06	8.47e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—TP53—ocular cancer	4.81e-06	8.45e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CCND1—ocular cancer	4.78e-06	8.4e-06	CbGpPWpGaD
Sunitinib—TYK2—Immune System—HRAS—ocular cancer	4.71e-06	8.28e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MDM2—ocular cancer	4.71e-06	8.27e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—MYC—ocular cancer	4.69e-06	8.25e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CCND1—ocular cancer	4.69e-06	8.25e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CCND1—ocular cancer	4.69e-06	8.25e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—TGFB1—ocular cancer	4.68e-06	8.23e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CDKN1A—ocular cancer	4.68e-06	8.22e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CDKN1B—ocular cancer	4.67e-06	8.2e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CDKN1B—ocular cancer	4.65e-06	8.18e-06	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—HRAS—ocular cancer	4.65e-06	8.18e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—HRAS—ocular cancer	4.64e-06	8.16e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CDKN1A—ocular cancer	4.62e-06	8.12e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—HRAS—ocular cancer	4.6e-06	8.08e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MDM2—ocular cancer	4.59e-06	8.07e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—EP300—ocular cancer	4.58e-06	8.06e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—MYC—ocular cancer	4.58e-06	8.05e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—TGFB1—ocular cancer	4.57e-06	8.03e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—HRAS—ocular cancer	4.57e-06	8.03e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—HRAS—ocular cancer	4.57e-06	8.03e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—AKT1—ocular cancer	4.55e-06	8.01e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CDKN1A—ocular cancer	4.54e-06	7.98e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CDKN1A—ocular cancer	4.54e-06	7.98e-06	CbGpPWpGaD
Sunitinib—YES1—Immune System—AKT1—ocular cancer	4.52e-06	7.94e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CCND1—ocular cancer	4.45e-06	7.83e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—EP300—ocular cancer	4.45e-06	7.83e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CCND1—ocular cancer	4.44e-06	7.81e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MDM2—ocular cancer	4.43e-06	7.78e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—MYC—ocular cancer	4.42e-06	7.76e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—TP53—ocular cancer	4.41e-06	7.75e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—TGFB1—ocular cancer	4.4e-06	7.74e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MDM2—ocular cancer	4.4e-06	7.74e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EP300—ocular cancer	4.4e-06	7.73e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—MYC—ocular cancer	4.39e-06	7.72e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—TGFB1—ocular cancer	4.38e-06	7.7e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—HRAS—ocular cancer	4.37e-06	7.68e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—AKT1—ocular cancer	4.37e-06	7.68e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—HRAS—ocular cancer	4.35e-06	7.65e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—HRAS—ocular cancer	4.34e-06	7.62e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—HRAS—ocular cancer	4.33e-06	7.61e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EP300—ocular cancer	4.32e-06	7.59e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EP300—ocular cancer	4.32e-06	7.59e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CDKN1A—ocular cancer	4.31e-06	7.57e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CDKN1B—ocular cancer	4.3e-06	7.55e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—HRAS—ocular cancer	4.3e-06	7.55e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CDKN1A—ocular cancer	4.29e-06	7.55e-06	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—AKT1—ocular cancer	4.29e-06	7.53e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—TP53—ocular cancer	4.24e-06	7.46e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—HRAS—ocular cancer	4.22e-06	7.42e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—TP53—ocular cancer	4.22e-06	7.41e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—HRAS—ocular cancer	4.21e-06	7.41e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—MYC—ocular cancer	4.21e-06	7.41e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MDM2—ocular cancer	4.21e-06	7.4e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TGFB1—ocular cancer	4.2e-06	7.39e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—MYC—ocular cancer	4.2e-06	7.38e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CDKN1B—ocular cancer	4.19e-06	7.37e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—TGFB1—ocular cancer	4.19e-06	7.36e-06	CbGpPWpGaD
Sunitinib—TYK2—Immune System—AKT1—ocular cancer	4.16e-06	7.31e-06	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—AKT1—ocular cancer	4.11e-06	7.22e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CCND1—ocular cancer	4.1e-06	7.21e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—AKT1—ocular cancer	4.1e-06	7.2e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EP300—ocular cancer	4.1e-06	7.2e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—HRAS—ocular cancer	4.09e-06	7.19e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TP53—ocular cancer	4.09e-06	7.19e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TP53—ocular cancer	4.09e-06	7.19e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EP300—ocular cancer	4.09e-06	7.18e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—AKT1—ocular cancer	4.06e-06	7.14e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—HRAS—ocular cancer	4.06e-06	7.14e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CDKN1B—ocular cancer	4.04e-06	7.1e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—AKT1—ocular cancer	4.03e-06	7.09e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—AKT1—ocular cancer	4.03e-06	7.09e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—HRAS—ocular cancer	4.03e-06	7.09e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CDKN1B—ocular cancer	4.02e-06	7.07e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—HRAS—ocular cancer	4e-06	7.04e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CCND1—ocular cancer	4e-06	7.03e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MYC—ocular cancer	4e-06	7.02e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—HRAS—ocular cancer	3.99e-06	7.02e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—HRAS—ocular cancer	3.99e-06	7.02e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TGFB1—ocular cancer	3.99e-06	7.01e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TP53—ocular cancer	3.98e-06	7e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CDKN1A—ocular cancer	3.96e-06	6.97e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—HRAS—ocular cancer	3.91e-06	6.87e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—HRAS—ocular cancer	3.91e-06	6.87e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—HRAS—ocular cancer	3.91e-06	6.87e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—HRAS—ocular cancer	3.9e-06	6.85e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MYC—ocular cancer	3.88e-06	6.82e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CDKN1A—ocular cancer	3.87e-06	6.8e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TGFB1—ocular cancer	3.87e-06	6.8e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—AKT1—ocular cancer	3.86e-06	6.79e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CCND1—ocular cancer	3.85e-06	6.78e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CDKN1B—ocular cancer	3.84e-06	6.75e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—AKT1—ocular cancer	3.84e-06	6.75e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CCND1—ocular cancer	3.83e-06	6.74e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MYC—ocular cancer	3.83e-06	6.73e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—AKT1—ocular cancer	3.83e-06	6.73e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TGFB1—ocular cancer	3.82e-06	6.72e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—AKT1—ocular cancer	3.82e-06	6.72e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—HRAS—ocular cancer	3.81e-06	6.7e-06	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—AKT1—ocular cancer	3.8e-06	6.68e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—AKT1—ocular cancer	3.79e-06	6.67e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EP300—ocular cancer	3.77e-06	6.63e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MYC—ocular cancer	3.76e-06	6.61e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MYC—ocular cancer	3.76e-06	6.61e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—HRAS—ocular cancer	3.76e-06	6.6e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TGFB1—ocular cancer	3.75e-06	6.6e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TGFB1—ocular cancer	3.75e-06	6.6e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—HRAS—ocular cancer	3.74e-06	6.57e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CDKN1A—ocular cancer	3.73e-06	6.56e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—AKT1—ocular cancer	3.73e-06	6.55e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—AKT1—ocular cancer	3.72e-06	6.54e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CDKN1A—ocular cancer	3.71e-06	6.52e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—HRAS—ocular cancer	3.69e-06	6.48e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EP300—ocular cancer	3.68e-06	6.47e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCND1—ocular cancer	3.66e-06	6.44e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—AKT1—ocular cancer	3.61e-06	6.35e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—HRAS—ocular cancer	3.6e-06	6.33e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—AKT1—ocular cancer	3.58e-06	6.3e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—HRAS—ocular cancer	3.57e-06	6.28e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MYC—ocular cancer	3.57e-06	6.28e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TGFB1—ocular cancer	3.56e-06	6.26e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MYC—ocular cancer	3.56e-06	6.26e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—AKT1—ocular cancer	3.56e-06	6.26e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TGFB1—ocular cancer	3.55e-06	6.25e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EP300—ocular cancer	3.55e-06	6.24e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CDKN1A—ocular cancer	3.54e-06	6.23e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—AKT1—ocular cancer	3.54e-06	6.22e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EP300—ocular cancer	3.53e-06	6.21e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—AKT1—ocular cancer	3.53e-06	6.2e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—AKT1—ocular cancer	3.53e-06	6.2e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—HRAS—ocular cancer	3.47e-06	6.1e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—ocular cancer	3.46e-06	6.08e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—AKT1—ocular cancer	3.45e-06	6.07e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—AKT1—ocular cancer	3.45e-06	6.07e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—AKT1—ocular cancer	3.45e-06	6.07e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—HRAS—ocular cancer	3.45e-06	6.06e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—AKT1—ocular cancer	3.44e-06	6.05e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—EP300—ocular cancer	3.42e-06	6.02e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GNA11—ocular cancer	3.41e-06	6e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—EP300—ocular cancer	3.39e-06	5.96e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EP300—ocular cancer	3.37e-06	5.93e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—AKT1—ocular cancer	3.36e-06	5.92e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—AKT1—ocular cancer	3.32e-06	5.83e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—HRAS—ocular cancer	3.31e-06	5.82e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—AKT1—ocular cancer	3.3e-06	5.8e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—HRAS—ocular cancer	3.3e-06	5.8e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MYC—ocular cancer	3.29e-06	5.78e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—ocular cancer	3.28e-06	5.77e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TGFB1—ocular cancer	3.28e-06	5.77e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—AKT1—ocular cancer	3.26e-06	5.72e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MYC—ocular cancer	3.21e-06	5.64e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TGFB1—ocular cancer	3.2e-06	5.63e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—ocular cancer	3.19e-06	5.6e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—AKT1—ocular cancer	3.18e-06	5.59e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GNAQ—ocular cancer	3.17e-06	5.58e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—AKT1—ocular cancer	3.15e-06	5.54e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—ocular cancer	3.15e-06	5.53e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—HRAS—ocular cancer	3.14e-06	5.52e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MYC—ocular cancer	3.09e-06	5.44e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—ocular cancer	3.09e-06	5.43e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—ocular cancer	3.09e-06	5.43e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TGFB1—ocular cancer	3.08e-06	5.42e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MYC—ocular cancer	3.08e-06	5.41e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TGFB1—ocular cancer	3.07e-06	5.39e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—AKT1—ocular cancer	3.06e-06	5.38e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—HRAS—ocular cancer	3.05e-06	5.36e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—AKT1—ocular cancer	3.05e-06	5.36e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—HRAS—ocular cancer	3.01e-06	5.29e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—HRAS—ocular cancer	2.95e-06	5.19e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—HRAS—ocular cancer	2.95e-06	5.19e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MYC—ocular cancer	2.94e-06	5.17e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TGFB1—ocular cancer	2.93e-06	5.16e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—ocular cancer	2.93e-06	5.15e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—ocular cancer	2.92e-06	5.14e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—AKT1—ocular cancer	2.92e-06	5.14e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—AKT1—ocular cancer	2.91e-06	5.12e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—HRAS—ocular cancer	2.8e-06	4.93e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—HRAS—ocular cancer	2.8e-06	4.92e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—AKT1—ocular cancer	2.77e-06	4.87e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—ocular cancer	2.7e-06	4.75e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—AKT1—ocular cancer	2.69e-06	4.73e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—AKT1—ocular cancer	2.66e-06	4.67e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—ocular cancer	2.63e-06	4.63e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—AKT1—ocular cancer	2.61e-06	4.59e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—AKT1—ocular cancer	2.61e-06	4.59e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HRAS—ocular cancer	2.58e-06	4.54e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—ocular cancer	2.54e-06	4.46e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—ocular cancer	2.53e-06	4.44e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HRAS—ocular cancer	2.52e-06	4.43e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—AKT1—ocular cancer	2.48e-06	4.35e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—AKT1—ocular cancer	2.47e-06	4.34e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—EP300—ocular cancer	2.45e-06	4.31e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HRAS—ocular cancer	2.43e-06	4.27e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HRAS—ocular cancer	2.42e-06	4.25e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—ocular cancer	2.41e-06	4.24e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HRAS—ocular cancer	2.31e-06	4.06e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—AKT1—ocular cancer	2.28e-06	4.01e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—AKT1—ocular cancer	2.22e-06	3.91e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—AKT1—ocular cancer	2.14e-06	3.77e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—AKT1—ocular cancer	2.13e-06	3.75e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—AKT1—ocular cancer	2.07e-06	3.64e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—AKT1—ocular cancer	2.05e-06	3.6e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—AKT1—ocular cancer	2.04e-06	3.58e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—EP300—ocular cancer	1.85e-06	3.25e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—AKT1—ocular cancer	1.48e-06	2.61e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—EP300—ocular cancer	1.14e-06	2e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—AKT1—ocular cancer	1.12e-06	1.97e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AKT1—ocular cancer	6.89e-07	1.21e-06	CbGpPWpGaD
